Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
23.13 CNY +1.45% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. -6.81% -7.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023 CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration MT
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug MT
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs MT
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator MT
Yuyuan Tourist Mart CFO Steps Down MT
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug MT
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd. CI
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets MT
Fosun Pharma Board Approves Unlocking, Vesting of Shares MT
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited CI
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement MT
Fosun Pharmaceutical's Unit Scraps Clinical Trial on ORIN1001 Tablet MT
China Accepts Drug Registration Application for Fosun Pharma Unit's Breast Cancer Treatment MT
Fosun Pharmaceutical's Unit Gets Greenlight to Test Cancer Drug in US, China MT
China Excludes Fosun Kite's Yescarta from Medical Insurance Program MT
Chinese Regulator Accepts New Drug Application for Embolism Drug by Fosun Pharmaceutical's Unit MT
Fosun Pharma Unit Obtains Marketing Rights to Desmopressin in China MT
India's Gland Pharma misses Q2 profit view on higher expenses RE
Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
More charts
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and hospital services (10.5%); - other (0.1%). China accounts for 72.9% of net sales.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
23.13 CNY
Average target price
31.18 CNY
Spread / Average Target
+34.80%
Consensus